Navigation Links
Plato BioPharma Presenting Poster at the American Thoracic Society Conference
Date:5/4/2011

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011.  The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of Gilead Sciences, Inc. and  Craig Plato, PhD, CEO of Plato BioPharma, Inc.

"Human Idiopathic Pulmonary Fibrosis has no known effective treatment, and a dramatically poor prognosis," said Dr. Plato.  "The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease.  Importantly, for the first time, clinically-relevant functional endpoints such as arterial blood gases, lung function, and pulmonary hemodynamics have been utilized, in part, to reveal the benefit of selective endothelin receptor antagonism."

"One of PBI's key strengths is to leverage and impart our years of experience, expertise, and technology for every study we conduct.  This approach offers clients an advantage over a typical contract research organization or functional service provider relationship.  We strive to be an integral partner with our clients, delivering cutting-edge, high-resolution disease modeling and methods as well as insightful solutions to preclinical drug discovery challenges," said Dr. Plato.  "I believe our joint presentation with Gilead at this year's ATS shows our commitment to these goals and value-add for our clients."

Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  A research team led by ... discovered details of how the abnormal breakage and rearrangement ... aggressive form of acute lymphoblastic leukemia (ALL). Such leukemias ... mutations trigger overproduction of immature cells, called lymphoblasts. ... of the malfunction underlying the type called "Ph-like ALL" ...
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016 /PRNewswire/--  ... have announced that advanced tissue-engineering services are now ... using a groundbreaking new three-dimensional (3D) bioprinting approach ... Regenova® 3D Bio Printer , a state-of-the-art robotic ... Applications has created a powerful pay-for-service bio-printing model ...
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ... the "Label-Free Detection Market by Technology, ... report to their offering. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Eating disorders and post-traumatic stress disorder ... and men with eating disorders report a history of trauma, research suggests that ... an eating disorder. , At the 2016 iaedp Symposium, the workshop, “What ...
(Date:2/8/2016)... ... 08, 2016 , ... The Association of Home Care Coding ... Home Health and Hospice ICD-10 Transition Workgroup are working closely with the American ... clarifications, to address concerns over the use of 'A' as the seventh character ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... quickly and easily add warm color grades to their footage. A LUT is a ... every pixel's color to the corresponding color indicated by the table. By manipulating each ...
Breaking Medicine News(10 mins):